Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Position Lifted by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL boosted its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 314.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 169,043 shares of the medical device company's stock after buying an additional 128,294 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.26% of Tandem Diabetes Care worth $6,089,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TNDM. Arizona State Retirement System boosted its position in Tandem Diabetes Care by 1.9% during the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock valued at $683,000 after purchasing an additional 362 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Tandem Diabetes Care by 4.3% during the 4th quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock valued at $360,000 after buying an additional 409 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in Tandem Diabetes Care by 8.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company's stock worth $247,000 after buying an additional 525 shares during the last quarter. Assetmark Inc. raised its position in Tandem Diabetes Care by 77.5% during the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after acquiring an additional 535 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares during the last quarter.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TNDM has been the topic of a number of recent research reports. Wells Fargo & Company restated an "equal weight" rating and set a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Morgan Stanley cut Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Mizuho started coverage on Tandem Diabetes Care in a report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective on the stock. Barclays reduced their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.81.

Tandem Diabetes Care Trading Up 0.5 %

Shares of TNDM opened at $16.85 on Thursday. The stock's 50-day moving average price is $19.30 and its 200 day moving average price is $28.87. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -8.73 and a beta of 1.52.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.